The role of DNA breaks in genomic instability and tumorigenesis

Immunological Reviews

Volumn 194, Issue , 2003, Pages 77-95

  Mills, Kevin D ^a   Ferguson, David O ^a,b   Alt, Frederick W ^a,c  

^a CENTER FOR BLOOD RESEARCH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; CELL METABOLISM; CELL TRANSFORMATION; CHROMOSOME DAMAGE; DISEASE ASSOCIATION; DNA REPAIR; DNA STRAND BREAKAGE; GENE MUTATION; GENETIC STABILITY; GENOME; KARYOTYPE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA; DNA DAMAGE; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; RECOMBINATION, GENETIC;

EID: 0037660900     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00060.x     Document Type: Review

References (198)

1. Kharma KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-254.
2. Ferguson DO, Alt FW. DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene 2001;20:5572-5559.
3. Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell 2002;109:S45-S55.
4. Hesslein DGT, Schatz DG. Factors and forces controlling V(D)J recombination. Adv Immunol 2001;78:169-232.
5. Fugmann SD, Lee AI, Shockett PE, Villey IJ, Schatz DG. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol 2000;18:495-527.
6. Willerford DM, Swat W, Alt FW. Developmental regulation of V(D)J recombination and lymphocyte differentiation. Curr Opin Genet Dev 1996;6:603-609.
7. Gorman JR, Alt FW. Regulation of immunoglobulin light chain isotype expression. Adv Immunol 1998;69:113-181.
8. Berg LJ, Kang J. Molecular determinants of TCR expression and selection. Curr Opin Immunol 2001;13:232-241.
9. Nagaoka H, Yu W, Nussenzweig MC. Regulation of RAG expression in developing lymphocytes. Curr Opin Immunol 2000;12:187-190.
10. Grawunder U, Winkler TH, Melchers F. Regulation of recombination activating gene expression during lymphocyte development. Curr Top Microbiol Immunol 1996;217:31-43.
11. Lin WC, Desiderio S. V(D)J recombination and the cell cycle. Immunol Today 1995;16:279-289.
12. Monroe RJ, et al. RAG2: GFP knockin mice reveal novel aspects of RAG2 expression in primary and peripheral lymphoid tissues. Immunity 1999;11:201-212.
13. Yu W, et al. Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization. Nature 1999;400:682-687.
14. Nemazee D, Weigert M. Revising B cell receptors. J Exp Med 2000;191:1813-1817.
15. Taccioli GE, Cheng HL, Varghese AJ, Whitmore G, Alt FW. A DNA repair defect in Chinese hamster ovary cells affects V(D)J recombination similarly to the routine scid mutation. J Biol Chem 1994;269:7439-7442.
16. Taccioli GE, Rathbun G, Oltz E, Stamato T, Jeggo PA, Alt FW. Impairment of V(D)J recombination in double-strand break repair mutants. Science 1993;260:207-210.
17. Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 1991;9:323-350.
18. Lee SH, Kim CH. DNA-dependent protein kinase complex: a multifunctional protein in DNA repair and damage checkpoint. Mol Ceils 2002;13:159-166.
19. Tuteja R, Tuteja N. Ku autoantigen: a multifunctional DNA-binding protein. Crit Rev Biochem Mol Biol 2000;35:1-33.
20. Lieber MR, Grawunder U, Wu X, Yaneva M. Tying loose ends: roles of Ku and DNA-dependent protein kinase in the repair of double-strand breaks. Curr Opin Genet Dev 1997;7:99-104.
21. Jeggo P, O'Neill P. The Greek goddess, Artemis, reveals the secrets of her cleavage. DNA Repair (Amst) 2002;1:771-777.
22. Critchlow SE, Jackson SP. DNA end-joining: from yeast to man. Trends Biochem Sci 1998;23:394-398.
23. Poltoratsky VP, Shi X, York JD, Lieber MR, Carter TH. Human DNA-activated protein kinase (DNA-PK) is homologous to phosphatidylinositol kinases. J Immunol 1995;155:4529-4533.
24. Grawunder U, Harfst E. How to make ends meet in V(D)J recombination. Curr Opin Immunol 2001;13:186-194.
25. Nick McElhinny SA, Snowden CM, McCarville J, Ramsden DA. Ku recruits the XRCC4-ligase IV complex to DNA ends. Mol Cell Biol 2000;20:2996-3003.
26. Schlissel MS. Does artemis end the hunt for the hairpin-opening activity in V(D)J recombination? Cell 2002;109:1-4.
27. Li L, et al. A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J Immunol 2002;168:6323-6329.
28. Moshous D, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001;105:177-186.
29. Noordzij JG, et al. Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-BCR checkpoint in bone marrow. Blood 2002;24:24.
30. Nicolas N, et al. A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J Exp Med 1998;188:627-634.
31. Rooney S, et al. Leaky scid phenotype associated with defective v(d)j coding end processing in artemis-deficient mice. Mol Cell 2002;10:1379-1390.
32. Ma Y, Pannicke U, Schwarz K, Lieber MR. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 2002;108: 781-794.
33. Rooney S, et al. Defective DNA repair and increased genome instability in Artemis-deficient murine cells. J Exp Med 2003;197:553-565.
34. Fukumura R, et al. Signal joint formation is also impaired in DNA-dependent protein kinase catalytic subunit knockout cells. J Immunol 2000;165:3883-3889.
35. Kurimasa A, et al. Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Nad Acad Sci USA 1999;96:1403-1408.
36. Gao Y, Chaudhuri J, Zhu C, Davidson L, Weaver DT, Alt FW. A targeted DNA-PKcs-null mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. Immunity 1998;9:367-376.
37. Taccioli GE, et al. Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers severe combined immunodeficiency and radiosensitivity. Immunity 1998;9:355-366.
38. Mondello C, Rebuzzini P, Dolzan M, Edmonson S, Taccioli GE, Giulotto E. Increased gene amplification in immortal rodent cells deficient for the DNA-dependent protein kinase catalytic subunit. Cancer Res 2001;61:4520-4525.
39. Barnes DE, Stamp G, Rosewell I, Denzel A, Lindahl T. Targeted disruption of the gene encoding DNA ligase IV leads to lethality in embryomc mice. Curr Biol 1998;8:1395-1398.
40. Gao Y, et al. A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell 1998;95:891-902.
41. Frank KM, et al. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 1998;396:173-177.
42. Gu Y, et al. Defective embryonic neurogenesis in Ku-deficient but not DNA-dependent protein kinase catalytic subunit-deficient mice. Proc Nad Acad Sci USA 2000;97:2668-2673.
43. Sekiguchi JM, et al. Non-homologous end-joining proteins are required for V(D)J recombination, normal growth and neurogenesis. Cold Spring Harb Symp Quant Biol 1999;64:169-181.
44. Karanjawala ZE, et al. The embryonic lethality in DNA ligase IV-deficient mice is rescued by deletion of Ku: implications for unifying the heterogeneous phenotypes of NHEJ mutants. DNA Repair (Amst) 2002;1:1017-1026.
45. Frank KM, et al. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol Cell 2000;5:993-1002.
46. Gao Y, et al. Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 2000;404:897-900.
47. Difilippantonio MJ, et al. DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 2000;404:510-514.
48. Manis JP, Tian M, Alt FW. Mechanism and control of class-switch recombination. Trends Immunol 2002;23:31-39.
49. Kinoshita K, Honjo T. Unique and unprecedented recombination mechanisms in class switching. Curr Opin Immunol 2000;12:195-198.
50. Casellas R, et al. Ku80 is required for immunoglobulin isotype switching. EMBO J 1998;17:2404-2411.
51. Manis JP, et al. Ku70 is required for late B cell development and immunoglobulin heavy chain class switching. J Exp Med 1998;187:2081-2089.
52. Rolink A, Melchers F, Andersson J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 1996;5:319-330.
53. Muramatsu M, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase famfiy in germinal center B cells. J Biol Chem 1999;274:18470-18476.
54. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-563.
55. Revy P, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 2000;102:565-575.
56. Storb U, Stavnezer J. Immunoglobulin genes: generating diversity with AID and UNG. Curr Biol 2002;12:R725-R727.
57. Rada C, Williams GT, Nilsen H, Barnes DE, Lindahl T, Neuberger MS. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Curr Biol 2002;12:1748-1755.
58. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 2003;422:726-730.
59. Sale JE, Calandrini DM, Takata M, Takeda S, Neuberger MS. Ablation of XRCC2/3 transforms immunoglobulin V gene conversion into somatic hypermutation. Nature 2001;412:921-926.
60. Di Noia J, Neuberger MS. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 2002;419:43-48.
61. Papavasiliou FN, Schatz DG. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 2002;109:S35-S44.
62. Wiesendanger M, Scharff MID, Edelmann W. Somatic hypermutation, transcription, and DNA mismatch repair. Cell 1998;94:415-418.
63. Longacre A, Storb U. A novel cytidine deaminase affects antibody diversity. Cell 2000;102:541-544.
64. Bross L, Fukita Y, McBlane F, Demolliere C, Rajewsky K, Jacobs H. DNA double-strand breaks in immunoglobulin genes undergoing somatic hypermutation. Immunity 2000;13:589-897.
65. Bross L, Muramatsu M, Kinoshita K, Honjo T, Jacobs H. DNA double-strand breaks: prior to but not sufficient in targeting hypermutation. J Exp Med 2002;195:1187-1192.
66. Papavasiliou FN, Schatz DG. The activation-induced deaminase functions in a postcleavage step of the somatic hypermutation process. J Exp Med 2002;195:1193-1198.
67. Chua KF, Alt FW, Manis JP. The function of AID in somatic mutation and class switch recombination: upstream or downstream of DNA breaks. J Exp Med 2002;195:F37-F41.
68. Bosma GC, et al. DNA-dependent protein kinase activity is not required for immunoglobulin class switching. J Exp Med 2002;196:1483-1495.
69. Manis JP, Dudley D, Kaylor L, Alt FW. IgH class switch recombination to IgG1 in DNA-PKcs-deflcient B cells. Immunity 2002;16:607-617.
70. Bemark M, Sale JE, Kim HJ, Berek C, Cosgrove RA, Neuberger MS. Somatic hypermutation in the absence of DNA-dependent protein kinase catalytic subunit (DNA-PK(cs)) or recombination-activating gene (RAG)1 activity. J Exp Med 2000;192:1509-1514.
71. Arakawa H, Hanschild J, Buerstedde JM. Requirement of the activation-induced deaminase (AID) gene for immunoglobuhn gene conversion. Science 2002;295:1301-1306.
72. Migliore L, Coppede F. Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res 2002;512:135-153.
73. Pages V, Fuchs RP. How DNA lesions are turned into mutations within cells? Oncogene 2002;21:8957-8966.
74. Yu S, et al. Human chromosomal fragile site FRA16B is an amplified AT-rich minisatellite repeat. Cell 1997;88:367-374.
75. Casper AM, Nghiem P, Arlt MF, Glover TW. ATR regulates fragile site stability. Cell 2002;111:779-789.
76. Glover TW, Stein CK. Induction of sister chromatid exchanges at common fragile sites. Am J Hum Genet 1987;41:882-890.
77. Coquelle A, Rozier L, Dutrillaux B, Debatisse M. Induction of multiple double-strand breaks within an hsr by meganucleaseI-SceI expression or fragile site activation leads to formation of double minutes and other chromosomal rearrangements. Oncogene 2002;21:7671-7679.
78. Hellman A, et al. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell 2002;1:89-97.
79. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 1998;2:259-265.
80. Coquelle A, Pipiras E, Toledo F, Buttin G, Debatisse M. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 1997;89:215-225.
81. de Lange T. Protection of mammalian telomeres. Oncogene 2002;21:532-540.
82. Chan SW, Blackburn EH. New ways not to make ends meet telomerase, DNA damage proteins and heterochromatin. Oncogene 2002;21:553-563.
83. Hsu HL, et al. Ku acts in a unique way at the mammalian telomere to prevent end joining. Genes Dev 2000;14:2807-2812.
84. Samper E, Goytisolo FA, Slijepcevic P, van Buul PP, Blasco MA. Mammalian Ku86 protein prevents telomeric fusions independently of the length of TTAGGG repeats and the G-strand overhang. EMBO Rep 2000;1:244-252.
85. Hsu HL, Gilley D, Blackburn EH, Chen DJ. Ku is associated with the telomere in mammals. Proc Natl Acad Sci USA 1999;96:12454-12458.
86. Espejel S, et al. Functional interaction between DNA-PKcs and telomerase in telomere length maintenance. EMBO J 2002;21:6275-6287.
87. Maser RS, DePinho RA. Take care of your chromosomes lest cancer take care of you. Cancer Cell 2003;3:4-6.
88. Chin L, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
89. Artandi SE, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000;406:641-645.
90. Smogorzewska A, Karlseder J, Holtgreve-Grez H, Janch A, de Lange T. DNA ligase IV-dependent NHEJ of deprotected mammalian telomeres in G1 and G2. Curr Biol 2002;12:1635-1644.
91. Adams JM, et al. c-myc-induced lymphomagenesis in transgenic mice and the role of the Pvt-1 locus in lymphoid neoplasia. Curr Top Microbiol Immunol 1986;132:1-8.
92. Adams JM, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-538.
93. Strasser A, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991;88:8661-8665.
94. Pettersson S, Cook GP, Bruggemann M, Williams GT, Neuberger MS. A second B cell-specific enhancer 3′ of the immunoglobulin heavy-chain locus. Nature 1990;344:165-168.
95. Khamlichi AA, Pinaud E, Decourt C, Chauveau C, Cogne M. The 3′ IgH regulatory region: a complex structure in a search for a function. Adv Immunol 2000;75:317-345.
96. Cogne M, et al. A class switch control region at the 3′ end of the immunoglobulin heavy chain locus. Cell 1994;77:737-747.
97. Pinaud E, et al. Localization of the 3′ IgH locus elements that effect long-distance regulation of class switch recombination. Immunity 2001;15:187-199.
98. Madisen L, Groudine M. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Genes Dev 1994;8:2212-2226.
99. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.
100. Wong S, Witte ON. Modeling Philadelphia chromosome positive leukemias. Oncogene 2001;20:5644-5659.
101. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 2002;99:409-426.
102. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001;20:5695-5707.
103. Gauwerky CE, Croce CM. Chromosomal translocations in leukaemia. Semin Cancer Biol 1993;4:333-340.
104. Kagan J, Croce CM. Molecular biology of lymphoid malignancies. Ann Oncol 1991;2:9-21.
105. Bailey SN, Rosenberg N. Assessing the pathogenic potential of the V(D)J recombinase by interlocus immunoglobulin hght-chain gene rearrangement. Mol Cell Biol 1997;17:887-894.
106. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 1978;253:1357-1370.
107. Schwab M. Amplification of oncogenes in human cancer cells. Bioessays 1998;20:473-479.
108. Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol 1999;9:319-325.
109. Paulson TG, Almasan A, Brody LL, Wahl GM. Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage. Mol Cell Biol 1998;18:3089-3100.
110. Ishizaka Y, Chernov MV, Burns CM, Stark GR. p53-dependent growth arrest of REF52 cells containing newly amplified DNA. Proc Natl Acad Sci USA 1995;92:3224-3228.
111. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;70:923-935.
112. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-948.
113. Gladdy RA, et al. The RAG-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-defcient mice. Cancer Cell 2003;3:37-50.
114. Zhu C, et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amphfication subsequent to translocations. Cell 2002;109:811-821.
115. Difilippantonio MJ, et al. Evidence for replicative repair of DNA double-strand breaks leading to oncogenic translocation and gene amplification. J Exp Med 2002;196:469-480.
116. Hayashi Y. The molecular genetics of recurring chromosome abnormalities in acute myeloid leukemia. Semin Hematol 2000;37:368-380.
117. Bartram CR. Molecular genetic aspects of myelodysplastic syndromes. Hematol Oncol Clin North Am 1992;6:557-570.
118. Dubourg C, et al. Evaluation of ETP1/eRF1, mapping to 5q31, as a candidate myeloid tumor suppressor gene. Cancer Genet Cytogenet 2002;134:33-37.
119. Dohner H, Stilgenbaner S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med 1999;77:266-281.
120. Liu Y, et al. 13q deletions in lymphoid malignancies. Blood 1995;86:1911-1915.
121. Rondeau G, et al. Comprehensive analysis of a large genomic sequence at the putative B- cell chronic lymphocytic leukaemia (B-CLL) tumour suppresser gene locus. Mutat Res 2001;458:55-70.
122. Davila M, Foster S, Kelsoe G, Yang K. A role for secondary V(D)J recombination in oncogenic chromosomal translocations? Adv Cancer Res 2001;81:61-92.
123. Kuppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 2001;20:5580-5594.
124. Hilgenfeld E, Padilla-Nash H, Schrock E, Ried T. Analysis of B-cell neoplasias by spectral karyotyping (SKY). Curr Top Microbiol Immunol 1999;246:169-174.
125. Roth DB, Craig NL. VDJ recombination: a transposase goes to work. Cell 1998;94:411-414.
126. Korsmeyer SJ. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol 1992;10:785-807.
127. Hecht JL, Aster JC. Molecular biology of Burkitt's lymphoma. J Clin Oncol 2000;18:3707-3721.
128. Chapman CJ, Wright D, Stevenson FK. Insight into Burkitt's lymphoma from immunoglobulin variable region gene analysis. Leuk Lymphoma 1998;30:257-267.
129. Stamatopoulos K, Kosmas C, Belessi C, Stavroyianni N, Kyriazopoulos P, Papadaki T. Molecular insights into the immunopathogenesis of follicular lymphoma. Immunol Today 2000;21:298-305.
130. Nadel B, Marculescu R, Le T, Rudnicki M, Bocskor S, Jager U. Novel insights into the mechanism of t (14;18)(q32;q21) translocation in follicular lymphoma. Leuk Lymphoma 2001;42:1181-1194.
131. Kuppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520-1529.
132. Ohmori H, Hikida M. Expression and function of recombination activating genes in mature B cells. Crit Rev Immunol 1998;18:221-235.
133. Knecht H, Brousset P, Bachmann E, Pallesen G, Odermatt BF. Expression of human recombination activating genes (RAG-1 and RAG-2) in lymphoma. Leuk Lymphoma 1994;15:399-403.
134. Bahler DW, Zelenetz AD, Chen TT, Levy R. Antigen selection in human lymphomagenesis. Cancer Res 1992;52 (Suppl. 19):5547s-5551s.
135. Bahler DW, Levy R. Clonal evolution of a follicular lymphoma: evidence for antigen selection. Proc Natl Acad Sci USA 1992;89:6770-6674.
136. Zelenetz AD, et al. Follicular lymphoma: a model of lymphoid tumor progression in man. Ann Oncol 1991;2:115-122.
137. Niu H. The proto-oncogene BCL-6 in normal and malignant B cell development. Hematol Oncol 2002;20:155-166.
138. Dalla-Favera R, et al. BCL-6 and the molecular pathogenesis of B-cell lymphoma Cold Spring Harb Symp Quant Biol 1994;59:117-123.
139. Fanning L, Bertrand FE, Steinberg C, Wu GE. Molecular mechanisms involved in receptor editing at the Ig heavy chain locus. Int Immunol 1998;10:241-246.
140. Klein G. Immunoglobulin gene associated chromosomal translocations in B-cell derived tumors. Curr Top Microbiol Immunol 1999;246:161-167.
141. Potter M, Wiener F. Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. Carcinogenesis 1992;13:1681-1697.
142. Potter M. Perspectives on the origins of multiple myeloma and plasmacytomas in mice. Hematol Oncol Clin North Am 1992;6:211-223.
143. Klein G. Constitutive activation of oncogenes by chromosomal translocations in B-cell derived tumors. AIDS Res 1986;2:S167-S176.
144. Ohno S, Babonits M, Wiener F, Spira J, Klein G, Potter M. Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell 1979;18:1001-1007.
145. Padilla-Nash HM, et al. Jumping translocations are common in solid tumor cell lines and result in recurrent fusions of whole chromosome arms. Genes Chromosomes Cancer 2001;30:349-363.
146. Aledo R, Aurias A, Chretien B, Dutrillaux B. Jumping translocation of chromosome 14 in a skin squamous cell carcinoma from a xeroderma pigmentosum patient. Cancer Genet Cytogenet 1988;33:29-33.
147. Tanaka K, Kamada N. Segmental jumping translocation in leukemia and lymphoma with a highly complex karyotype. Leuk Lymphoma 1998;29:563-575.
148. Coleman AE, Kovalchuk AL, Janz S, Pahni A, Ried T. Jumping translocation breakpoint regions lead to amplification of rearranged Myc. Blood 1999;93:4442-4444.
149. Kohl NE, Gee CE, Alt FW. Activated expression of the N-myc gene in human neuroblastomas and related tumors. Science 1984;226:1335-1337.
150. Kohl NE, et al. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 1983;35:359-367.
151. Schwab M, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-248.
152. Seeger RC, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-1116.
153. Streubel B, et al. Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. Genes Chromosomes Cancer 2000;27:380-386.
154. Reddy KS, et al. Segmental amplification of 11q23 region identified by fluorescence in situ hybridization in four patients with myeloid disorders: a review. Cancer Genet Cytogenet 2001;126:139-146.
155. Streubel B, Valent P, Lechner K, Fonatsch C. Amplification of the AML1 (CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21. Cancer Genet Cytogenet 2001;124:42-46.
156. Sait SN, Qadir MU, Conroy JM, Matsin S, Nowak NJ, Baer MR. Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndrome: identification of new amplification regions by fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer 2002;34:42-47.
157. Van Limbergen H, et al. Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH. Genes Chromosomes Cancer 2002;33:60-72.
158. Struski S, Doco-Fenzy M, Cornillet-Lefebvre P. Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet 2002;135:63-90.
159. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nature Rev 2002;2:175-187.
160. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2001, 157-177.
161. Pratt G. Molecular aspects of multiple myeloma. Mol Pathol 2002;55:273-283.
162. Roddam PL, Rollinson S, O'Driscoll M, Jeggo PA, Jack A, Morgan GJ. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet 2002;39:900-905.
163. Lim DS, Vogel H, Willerford DM, Sands AT, Platt KA, Hasty P. Analysis of ku80-mutant mice and cells with deficient levels of p53. Mol Cell Biol 2000;20:3772-3780.
164. Vanasse GJ, et al. Genetic pathway to recurrent chromosome translocations in murine lymphoma involves V(D)J recombinase. J Clin Invest 1999;103:1669-1675.
165. Nacht M, et al. Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 1996;10:2055-2066.
166. Bogue MA, Wang C, Zhu C, Roth DB. V(D)J recombination in Ku86-deficient mice, distinct effects on coding, signal, and hybrid joint formation. Immunity 1997;7:37-47.
167. Li Z, et al. The XRCC4 gene encodes a novel protein revolved in DNA double-strand break repair and V(D)J recombination. Cell 1995;83:1079-1089.
168. Verkaik NS, et al. Different types of V(D)J recombination and end-joining defects in DNA double-strand break repair mutant mammalian cells. Eur J Immunol 2002;32:701-709.
169. Zhong Q, Chen CF, Chen PL, Lee WH. BRCA1 facilitates microhomology-mediated end joining of DNA double strand breaks. J Biol Chem 2002;277:28641-28647.
170. Li GC, et al. Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol Cell 1998;2:1-8.
171. Gu Y, et al. Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity 1997;7:653-665.
172. Jhappan C, Morse HC III, Fleischmann FD Gottesman MM Merlino G. DNA-PKcs: a T-cell tumour suppressor encoded at the mouse scid locus. Nat Genet 1997;17:483-486.
173. Custer RP Bosma GC Bosma MJ. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. Am J Pathol 1985;120:464-477.
174. Lee Y McKinnon PJ. DNA ligase IV suppresses medulloblastoma formation. Cancer Res 2002;62:6395-6399.
175. Donehower LA, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
176. Jacks T, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
177. Lee J, Desiderio S. Cychn A/CDK2 regulates V(D)J recombination by coordinating RAG-2 accumulation and DNA repair. Immunity 1999;11:771-781.
178. Lane DP, Cancer. p53, guardian of the genome. Nature 1992;358:15-16.
179. McClintock B. The stability of broken ends of chromosomes in Zea mays. Genetics 1941;26:234-282.
180. Stark GR. Regulation and mechanisms of mammalian gene amplification. Adv Cancer Res 1993;61:87-113.
181. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-649.
182. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature 2000;405:697-700.
183. Bosco G, Haber JE. Chromosome break-induced DNA replication leads to nonreciprocal translocations and telomere capture. Genetics 1998;150:1037-1047.
184. Pipiras E, Coquelle A, Bieth A, Debatisse M. Interstitial deletions and intrachromosomal amplification initiated from a double-strand break targeted to a mammalian chromosome. EMBO J 1998;17:325-333.
185. Singer MJ, Mesner LD, Friedman CL, Trask BJ, Hamlin JL. Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. Proc Natl Acad Sci USA 2000;97:7921-7926.
186. Sharpless NE, DePinho RA. p53: good cop/bad cop. Cell 2002;110:9-12.
187. Setlow RB. Human cancer: etiologic agents/dose-responses/DNA repair/cellular and animal models. Mutat Res 2001;477:1-6.
188. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003;3:23-34.
189. Thompson LH, Schild D. Recombinational DNA repair and human disease. Mutat Res 2002;509:49-78.
190. Taylor AM. Chromosome instability syndromes. Baillieres Best Pract Res Clin Haematol 2001;14:631-644.
191. Sharpless NE, et al. Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol Cell 2001;8:1187-1196.
192. O'Driscoll M, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 2001;8:1175-1185.
193. Moshous D, et al. Partial T and B lymphocyte immunodeficiency and predisposition to lymphoma in patients with hypomorphic mutations in Artemis. J Clin Invest 2003;111:381-387.
194. Duan Z, et al. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2002;11:1142-1143.
195. Shen H, Sturgis EM, Dahlstrom KR, Zheng Y, Spitz MR, Wei Q. A variant of the DNA repair gene XRCC3 and risk of squamous cell carcinoma of the head and neck: a case-control analysis. Int J Cancer 2002;99:869-872.
196. Kuschel B, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 2002;11:1399-1407.
197. Rafii S, et al. A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer. Hum Mol Genet 2002;11:1433-1438.
198. Winsey SL, et al. A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 2000;60:5612-5616.